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Abstract 
The current study examined whether laterality of initial motor symptom onset (left-sided 
onset vs. right-sided onset) in Parkinson’s disease (PD) would predict the pattern and/or severity of 
cognitive deficits measured at various stages of disease progression.  We evaluated the relationship 
between initial motor presenting symptoms obtained at the time of PD diagnosis and current 
cognitive profiles across three different patient groups (early unilateral, late unilateral, late bilateral 
stages of PD).  Findings lend some support for study hypotheses regarding a lateralization of 
cognitive deficits based on initial laterality of motor symptoms.  That is, right-sided motor symptom 
onset in PD was associated with diminished performance on left hemisphere cognitive measures, but 
the data did not reveal a significant relationship between left-sided motor symptom onset and 
impairment on right hemisphere measures.  The current study also revealed cognitive deficits 
consistent with hypothesized effects of disease progression, such that cognitive changes during the 
unilateral stages of PD seem restricted to executive dysfunction, whereas bilateral disease in PD 
(with greater than 5 years disease duration) is associated with more widespread cognitive decline.   
 
 2 
Laterality of Motor Symptom Onset, Disease Progression, and Cognition in Parkinson’s Disease 
 
Parkinson’s disease (PD) is a neurodegenerative movement disorder believed to be caused by 
nigrostriatal dopamine depletion and characterized by hallmark motor symptoms such as tremor, 
bradykinesia (i.e., slowness in voluntary movement), and muscular rigidity.  In James Parkinson’s 
original (1817) essay, he stated that “the senses and intellect were uninjured” in the illness that now 
bears his name, and PD has long since been characterized as a disorder restricted to the motor 
system.  However, there is increasing awareness that this disease process also involves a non-motor 
symptom complex that can include cognitive difficulties.  The cognitive difficulties associated with 
PD have not been well characterized.  While it has been established that dopamine depletion is 
associated with PD motor deficits, the specific neuropathology underlying cognitive impairment 
remains unclear. 
The research literature examining cognitive impairment in PD has grown considerably over 
the past two decades.  Cognitive deficits are most consistently observed in frontal-executive 
functions (Duke & Kaszniak, 2000; Taylor, Saint-Cyr, & Lang, 1986; Zgaljardic et al., 2006), 
particularly on tasks of working memory, planning, and cognitive set shifting (Cools, Barker, 
Sahakian, & Robbins, 2001).  These changes have been observed even early in the course of the 
disease (Cools et al., 2001).  Impairments in verbal, visuospatial, and memory functions have also 
been described, even in PD patients without dementia (Levin, Tomer, & Rey, 1992; Dubois & Pillon, 
1997), but reports have been inconsistent across studies.  These mixed results may be related to 
differences in patient selection factors across studies, including differences in disease progression 
which may be reflective of different subtypes of PD with and without cognitive decline.  In all, there 
appears to be significant heterogeneity in the cognitive course of PD.  Estimates of dementia in PD 
vary widely depending on the disease characteristics of particular study samples, but large scale 
epidemiological studies suggest that approximately 20-40% of patients will develop dementia in later 
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stages of the disorder (Marder, Tang, Cote, Stern, & Mayeux, 1995; Mayeux et al., 1992; Tison et al. 
1995).  While some PD patients do not appear to demonstrate significant cognitive deficits 
throughout the course of their illness, frontal-executive impairments are present over the course of 
PD in many patients, even in those who do not develop frank dementia (Duke & Kaszniak, 2000; 
Emre, 2003).    
Due to significant heterogeneity in the cognitive presentation of PD, there has been 
increasing interest in identifying which clinical variables may make patients more susceptible to 
cognitive decline and later development of comorbid dementia.  Although there is no clear 
consensus, the following clinical characteristics have been reported in the literature as potentially 
associated with increased cognitive deficits in PD: increased age at disease onset (Locascio, Corkin, 
& Growdon, 2003; Mayeux et al., 1992), longer duration of illness (Biggins et al., 1992), the 
presence of bilateral as opposed to unilateral motor symptoms (Gasparoli et al., 2002; Viitanen, 
Mortimer, & Webster, 1994), the presence of postural instability and unsteady gait (Alves, Larsen, 
Emre, Wentzel-Larsen, & Aarsland, 2006; Burn et al., 2006), and the severity of current motor 
symptoms (Locascio et al., 2003; Williams et al., 2007). These characteristics require further 
evaluation in studies of PD and cognition to elucidate their relative contributions to the disease 
course.  
One clinical disease feature that has been investigated pertains to laterality of initial motor 
symptoms – that is, whether motor symptoms are present on primarily the right or left side of the 
body.  In PD, a typical course of symptom progression involves unilateral onset of cardinal motor 
features (e.g., tremor, rigidity, bradykinesia), with a gradual progression to bilateral motor disease 
over the course of the disorder.  Multiple studies have demonstrated that the asymmetrical onset of 
motor symptoms is associated with degeneration of nigrostriatal dopaminergic neurons contralateral 
to the affected body side (Kempster, Gibb, Stern, & Lees, 1989; Nahmias, Garnett, Firnau, & Lang, 
1985, Rinne et al., 1993).  Therefore, initial side of motor symptom onset and current predominant 
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side of symptoms may be important markers of the underlying neuropathology.  However, research 
findings addressing neuropsychological disturbances on the basis of motor symptom laterality have 
been mixed.  Some studies have identified specific patterns of neuropsychological deficits in PD 
patients with right vs. left unilateral motor symptoms, while others have found minimal or no 
differences.  The effects of motor symptom asymmetry on cognitive profiles remain unclear, and 
consequently there is uncertainty whether the neuropathology in PD responsible for motor symptoms 
is also responsible for cognitive deficits. 
This paper will first briefly discuss the neuropathology of PD and review current hypotheses 
about the neuropathological basis of cognitive decline in this disorder.  We then evaluate the existing 
literature on the association between laterality of motor symptoms and cognition in PD and address 
methodological problems in previous studies (including failure to control for disease progression) 
that may account for the inconsistent findings.  Lastly, results of the current study, which addresses 
some limitations of past research, are reviewed and discussed.    
Neuropathology associated with different stages of Parkinson’s disease 
The neuropathological hallmark of PD is neuronal degeneration in the pars compacta of the 
substantia nigra, one of the nuclei clusters of the basal ganglia (Jellinger, 2001; Paulus & Jellinger, 
1991).  Neurons in the substantia nigra are the origin of the nigrostriatal pathways, which are 
responsible for both the excitatory and inhibitory dopaminergic innervation of the caudate and 
putamen (known collectively as the striatum) of the basal ganglia.  The striatum and associated 
regions contain more than 80% of the total dopamine in the brain, and the degree of striatal dopamine 
deficiency appears to be correlated with the severity of motor symptoms in PD (Leenders et al., 
1990; Wang et al., 2007).  There are multiple complex pathways that connect the striatum to the 
frontal cortex, and much evidence has accumulated for the role of these frontal-striatal circuits in 
movement, cognition, and behavior (see Lichter & Cummings, 2001 for a detailed review of these 
frontal-striatal circuits). 
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At the earliest stages of PD, mild cognitive abnormalities, when present, are hypothesized to 
be primarily the result of dopaminergic disruptions to frontal-striatal circuitry (Owen, 2004; 
Zgaljardic et al., 2006).  This is supported by functional neuroimaging studies showing selective 
underactivity in striatal and frontal lobe regions in the brains of early PD patients as compared to 
healthy controls during tasks of attention, working memory, and verbal fluency (Lewis, Dove, 
Robbins, Barker, & Owen, 2003; Rinne et al., 2000).  Additionally, neuropsychological studies 
(Dubois & Pillon, 1997; Lees & Smith, 1983) show that cognitive deficits during early stages of PD 
are relatively subtle and restricted primarily to tests of frontal networks dysfunction (e.g., executive 
function, working memory).  As the disease advances, however, more widespread cognitive deficits 
typically become apparent, even in the absence of dementia (Green et al., 2002).  This is consistent 
with evidence that other neuropathological mechanisms can also be involved in later stages of the 
disease.  These include diffuse Lewy body disease, comorbid Alzheimer’s pathology, and/or 
degeneration in non-dopaminergic (e.g., cholinergic, noradrenergic and serotonergic) neuronal 
systems (Braak et al., 2003, Dubois & Pillon, 1992; Emre, 2003; Galvin, 2006; Jellinger, 2001; 
Zdaljardic, Foldi, & Borod, 2004).  Consequently, in later stages of the disease, differential diagnosis 
can be challenging due to similar clinical presentations of PD with comorbid dementia (PDD), 
Alzheimer’s disease with Parkinsonian features, and dementia with Lewy bodies (Galvin, 2006; 
Jellinger, 2001).  Thus, when examining the neuropathology of PD, duration and stage of illness are 
believed to be highly relevant, since additional non-dopaminergic pathology is more likely to be 
present as the disease advances.         
The relationship between motor symptoms and cognition in PD 
The precise pathophysiological mechanisms underlying cognitive impairments in PD, as well 
as the relationship between motor and cognitive symptoms, are not well understood.  A number of 
studies have documented a significant relationship between motor disability and cognitive 
difficulties.  For example, severity and progression of current motor symptoms, as indexed by Hoehn 
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and Yahr stages or Part III of the Unified Parkinson’s Disease Rating Scale (UPDRS), have been 
associated with greater cognitive impairment, even after controlling for age and disease duration 
(Huber, Freidenberg, Shuttleworth, Paulson, & Christy, 1989; Locascio et al., 2003; Williams et al., 
2007).  Additionally, some researchers have demonstrated that patients with bilateral motor 
symptoms have more global cognitive impairment than patients with unilateral symptoms (Gasparoli 
et al., 2002; Starkstein & Leiguarda, 1993; Viitanen et al., 1994).  However, because of the increased 
likelihood of having additional non-dopaminergic pathology in later stages of the disease, it is 
unclear whether the cognitive impairment associated with disease progression is indeed related to the 
same dopaminergic pathology underlying motor symptoms.  Although some investigations suggest a 
close connection between motor symptoms and cognitive performance, other studies have reported 
weak or nonsignificant correlations.  For example, Cooper, Sagar, Jordan, Harvey, and Sullivan 
(1991) studied patients with newly diagnosed PD and found a strong association between UPDRS 
motor scores and depressive symptoms, but a weak correlation between motor disability and 
cognitive impairment.  The authors concluded that cognitive dysfunction, even in early PD, may 
reflect neuropathological changes that are distinct from the nigrostriatal dopamine depletion 
underlying motor symptomatology.  Although many studies suggest a significant association between 
motor disability and cognition, the predictive value of motor symptoms for subsequent cognitive 
decline remains controversial at present.  It would be important for future studies to clarify this 
relationship.       
For many patients, motor symptoms begin on one body side and remain unilateral for some 
time prior to bilateral involvement.  As noted previously, it is commonly believed that PD patients 
exhibit motor symptoms on the body side that is contralateral to the site of brain dysfunction 
(Blumenfeld, 2002).  Kempster et al.’s (1989) post mortem study found that asymmetrical motor 
symptomatology is associated with greater neuronal loss in the substantia nigra contralateral to the 
affected body side.  Nahmias et al. (1985) demonstrated the hypothesized asymmetry of 
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dopaminergic activity in patients with unilateral motor symptoms using positive emission 
tomography (PET), revealing that patients with right side motor symptoms had a significantly lower 
levodopa reuptake in the left striatum, and patients with left sided motor symptoms had decreased 
reuptake in the right striatum.  However, it is uncertain how these dopamine asymmetries may 
influence the cortex and cognitive functions.  If degeneration of the substantia nigra and striatal 
dopamine depletion remain largely asymmetrical for a period of time in PD, then these 
neuropathological asymmetries may have effects on cognition as well.  Because of the multiple 
complex frontal-subcortical pathways that originate from the striatum, it is plausible that these 
subcortical asymmetries could exert a distinct pattern of deficits in higher cortical functions.  Thus, 
examining the relationship between motor symptom asymmetry and cognition may help further our 
understanding of the pathophysiological basis of cognitive decline in PD.  There have been a number 
of studies examining this relationship, and these are reviewed in the next section.   
Previous research examining laterality of motor symptoms and cognition 
Research examining the relationship between motor symptom asymmetry and cognition can 
be divided into two categories: 1) studies that relate laterality of motor symptoms at the time of 
disease onset to cognition later in the disease course, and 2) studies that examine the relationship 
between current motor symptoms and current cognitive functioning.  Results from the latter category 
are discussed first.    
Studies investigating associations between current laterality of motor symptoms and current 
cognitive deficits have utilized a similar research design in that PD pati ents are typically divided on 
the basis of their motor symptom laterality.  That is, differences in neuropsychological performance 
are examined in patients with either right or left motor symptom predominance.  These investigations 
have yielded very mixed results.  Some researchers have found a clear lateralized cognitive profile, 
such that patients with predominantly right-sided motor symptoms (implying greater left hemisphere 
involvement) were more impaired on tests of language and verbal ability, and patients with 
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predominantly left-sided motor symptoms (implying greater right hemispheric disease involvement) 
performed more poorly on visuospatial tasks (Bentin, Silverberg, & Gordon, 1981; Blonder, Gur, 
Saykin, & Hurtig, 1989; Starkstein, Leiguarda, Gershanik, & Bertheier, 1987).  Other studies have 
found only partial support for the expected lateralized profile, such that right-sided motor symptoms 
were associated with greater impairment on tests of left hemisphere function, but no group 
differences were observed on tests assessing right hemisphere function (Huber, Miller, Bohaska, 
Christy, & Bornstein, 1992; Spicer, Roberts, & LeWitt, 1988).  Williams et al. (2007) found that a 
predominance of right-sided motor symptoms is associated with increased overall cognitive 
impairment, whereas another study found that patients with left-sided motor symptoms performed 
more poorly across a broad range of neuropsychological test measures (Direnfeld et al., 1984).  
Further complicating the picture, another set of studies show no significant differences between 
patients with unilateral right and unilateral left motor symptoms (Huber, Freidenberg, Shuttleworth, 
Paulson, & Clapp, 1989; St. Clair, Borod, Sliwinski, Cote, & Stern, 1998).  Consequently, it remains 
unclear whether motor symptoms are predictive of the severity and profile of cognitive deficits in 
patients with PD. 
These discrepant findings may be due to a number of methodological factors including small 
sample sizes, lack of control for disease progression, and inadequate selection and/or interpretation of 
neuropsychological measures.  In past studies, patients classified as “unilateral” may have also 
included patients who had progressed to the bilateral disease stage – but were nevertheless classified 
as unilateral patients due to a continuing motor asymmetry that was consistent with their initial 
presentation of motor symptoms.  In other words, they had more severe motor symptoms on one side 
than the other, but at the time of cognitive testing, their motor symptoms affected both sides of the 
body.  Because the relationship between laterality of motor symptoms and cognition may depend 
upon stage of disease, it would be important for future investigations to control for disease 
progression.  Additionally, studies have differed in their interpretations of what constitutes right vs. 
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left hemisphere cognitive tasks, and therefore may misinterpreted cognitive profiles with respect to 
hemispheric specialization.  For example, the Stroop Test was used in one study as a task of right 
hemisphere function (St. Clair et al., 1998) based on an earlier demonstration (Hietanen & 
Teravainen, 1989) that PD patients with primarily left-sided motor symptoms performed more poorly 
on the Stroop task than patients with right-sided motor symptoms.  In addition to the obvious visual 
nature of the task, the Stroop test also requires reading and rapid speech output (tasks often ascribed 
to the left hemisphere) as well as a strong attentional and executive component (functions that are not 
as lateralizing).  Additionally, verbal fluency has been included in previous studies as a measure of 
left hemisphere function (Blonder et al., 1989; Huber et al., 1989b; St. Clair et al., 1998), but it is 
also a task that is highly dependent upon intact attention and speed of processing.  Consequently, 
when interpreting hemispheric profiles reflective of asymmetric brain dysfunction, it is important to 
consider the multiple cognitive functions measured by each task.  
Some investigators have chosen to study whether laterality of motor symptoms at disease 
onset predicts cognitive deficits later in the disease course.  Tomer, Levin, and Weiner (1993) 
employed this research design with a mixed PD sample (average disease duration of six years) that 
included patients with both unilateral and bilateral disease at the time of neuropsychological testing.  
Tomer et al. found that, when examined later in the disease course, patients with initial left-sided 
motor symptoms consistently performed more poorly across a range of cognitive measures compared 
to patients with right-sided motor symptom onset.  Yet, another investigation (Viitanen et al., 1994) 
evaluated the cognitive profiles of PD patients in unilateral and bilateral stages (with an average 
disease duration of nine years), and found no significant pattern of differences between the 
performance of patients with right vs. left motor symptom onset.  Since both studies utilized patients 
who had both unilateral and bilateral motor symptoms at the time of neuropsychological testing, 
failure to control for disease progression may have confounded results and limited interpretation of 
these findings.   
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Despite some drawbacks of the Tomer et al. (1993) and Viitaenen et al. (1994) studies, there 
may be some advantages to examining the relationship between initial side of motor symptoms and 
later cognitive impairment, rather than examining how cognitive performance relates to current 
motor symptom profiles.  As noted by others (Katzen Levin, & Weiner, 2006; Tomer et al., 1993), 
one reason why it may be helpful to study side of motor symptoms at disease onset relates to the 
issue of medication usage in PD.  The effects of dopaminergic medications (i.e., dopamine 
replacement drugs such as levodopa, or dopamine agonist drugs such as bromocriptine or ropinirole) 
on cognition have been hotly debated in the research literature.  Investigations comparing medicated 
vs. unmedicated patients and those examining “on” and “off” medication states have indicated 
cognitive improvement, deterioration, or no changes, depending on the study (see Cools, 2008; or 
Pillon, Czernecki, & Dubois, 2003 for reviews on the complex relationship between dopamine and 
cognition).  Because of multiple studies suggesting an association between the use of dopaminergic 
medications and cognitive deterioration, medication usage becomes a relevant issue here.  Many PD 
patients begin dopaminergic drugs shortly after diagnosis and early in the course of their disease, and 
it is possible that these medications may contribute to the heterogeneity of cognitive symptoms 
observed in PD.  Additionally, these medications are known to suppress many of the motor 
abnormalities associated with PD.  After a period of time on these medications, it is possible that 
evaluation of current motor symptom severity may not accurately reflect the underlying 
neuropathology.  Therefore, laterality of motor symptom at disease onset may be an important 
marker of the underlying neuropathological changes and cognitive change, possibly more so than 
current motor symptomatology.  
Disease progression and cognition in PD 
Because cognitive deficits may be qualitatively and quantitatively different at various stages 
of PD, studies in recent decades have examined the role of disease progression on cognition in PD.  
Disease progression has been operationally defined a number of ways in previous investigations.  
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Some studies have characterized disease progression simply as illness duration (i.e., years since 
initial PD diagnosis).  Muslimovic, Schmand, Speelman, and De Haan (2007) conducted a meta-
analytic review of 25 longitudinal studies (ranging from 2-8 years between initial and follow-up 
assessment) examining disease duration and cognition in PD.  The authors examined aggregate 
differences between neuropsychological performance at baseline and follow-up, and reported small 
to moderate effect sizes across all cognitive domains examined.  In addition to longitudinal studies, 
investigations have employed cross-sectional designs.  These studies, examining differences between 
patients with varying levels of illness duration, also indicate that longer disease duration is associated 
with increased cognitive difficulties (Locascio, Corkin, & Growdon, 2003; Stern & Mayeux, 1986).   
However, one limitation with using illness duration as a marker of disease progression is that patients 
commonly progress at different rates due to the heterogeneity in PD.  For this reason, disease 
progression has been alternatively studied by assessing severity of motor symptoms (either by 
examining Hoehn and Yahr scores reflective of unilateral versus bilateral disease stages, or UPDRS 
scales assessing motor disability).  As discussed earlier, both Hoehn and Yahr stages and UPDRS 
scores appear to be associated with cognitive impairment in most studies (Gasparoli et al., 2002; 
Huber et al., 1989; Locascio et al., 2003; Starkstein & Leiguarda, 1993; Viitanen et al., 1994; 
Williams et al., 2007).  The implicit assumptions of these research designs should be noted – namely, 
that bilateral motor disease is reflective of a more advanced PD stage than unilateral motor disease, 
and that higher motor disability scores on standardized scales indicate more advanced disease 
progression.   
From the discussion thus far, it is clear that studies examining the relationship between motor 
symptoms and cognition in PD must control for disease severity/progression or otherwise consider 
how this might influence research findings.  The underlying neuropathology during early and later 
PD stages may involve different neuronal mechanisms, and this is likely to influence observed 
patterns of cognitive impairment.  However, disease progression has not been well controlled in 
 
 12 
previous neuropsychological studies of PD.  Many researchers have measured disease progression as 
a single construct or have examined motor symptom impairment, duration of disease, or stage of 
motor symptom progression (unilateral vs. bilateral) alone without considering the other variables.  
Thus, it may be helpful for future studies to tease apart specifically which dimensions of disease 
severity/progression (motor symptom severity, illness duration, or unilateral vs. bilateral motor 
involvement) are linked to cognitive difficulties.   
Rationale for the current study 
The current study examined whether laterality of motor symptom onset (left-sided onset vs. 
right-sided onset) in PD is related to the pattern of cognitive deficits observed at various stages of 
disease progression.  In contrast to previous studies, we evaluated how initial motor symptoms 
predicted cognitive performance in patient groups that differ with respect to both disease duration 
and severity – specifically, in patients who were in either the early unilateral, late unilateral, or late 
bilateral stages of PD.  By examining patients in three different current stages of disease progression, 
the present study may clarify whether disease progression can account for some of the heterogeneity 
in the results of previous studies.  Findings from this study may provide predictive information 
regarding the relationships between laterality of motor symptom onset, disease progression, and 
subsequent development of cognitive impairment.  These results may also shed light on the 
pathophysiological basis of cognitive impairment in PD. 
Study hypotheses 
The following hypotheses were derived from the previous discussion:   
1. The laterality of initial motor onset predicts the profile of cognitive impairment in the earlier 
stages of the disease.  We selected participants on the basis of either right or left unilateral 
motor symptom onset, and evaluated cognitive profiles at unilateral and bilateral stages of the 
disease (reflective of disease progression).  We predict that PD patients will show a pattern of 
lateralized cognitive deficits consistent with expected dopamine asymmetries only while they 
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are still in the unilateral stage of the disease.  Lateralized cognitive deficits are not expected 
for patients in the bilateral stage of disease progression.    
2. PD patients in the unilateral stage of the disease will display frontal-executive deficits, with 
the later unilateral group exhibiting more severe impairment than the early unilateral group.  
Utilizing a cross-sectional design, we will evaluate the cognitive profiles of PD patients in 
the unilateral stage of the disease across two different ranges of disease duration. We predict 
that PD patients in the (early and late) unilateral stages will exhibit a pattern of frontal-
executive, attention/working memory, and memory encoding deficits, consistent with the 
hypothesis of dopamine depletion as the primary pathology.  We expect that the late 
unilateral group (2-5 years since diagnosis) will show greater severity of impairment than the 
early unilateral group (<1 year since diagnosis), consistent with the hypothesized effects of 
disease progression.  
3. PD patients in the bilateral disease stage will exhibit more global cognitive deficits than 
patients in the unilateral stage.  We expect that the cognitive performance of PD patients in 
the bilateral stage will be significantly lower than that of age-matched controls and PD 
patients in the unilateral stage across most or all cognitive domains, consistent with 
hypothesized involvement of additional non-dopaminergic pathology in the later stages of the 
disorder.   
Method 
Participants 
Sixty participants with PD and 20 age-matched healthy adults were recruited for this study.  
All participants were between 51-77 years of age, were right handed as defined as by a score of >+60 
on the Edinburgh Handedness Inventory (Oldfield, 1971), were native English speakers, and had 
completed at least a high school education.  Demographic characteristics of PD and control groups 
are outlined in Table 1.  Exclusionary criteria for all participants included the following: history of 
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CNS disease other than PD, history of DSM-IV major psychiatric disorder, history of concurrent, 
unstable or serious medical condition, history of major head trauma, or history of neurosurgery.   
PD sample.  PD participants were nondemented (score of 25 or greater on the Mini Mental 
Status Examination) and had a diagnosis of idiopathic PD, as confirmed by the study’s collaborating 
neurologist (Rajesh Pahwa, M.D.), a movement disorders specialist.  PD patients were recruited from 
the PD and Movement Disorders Clinic at the University of Kansas Medical Center (KUMC).  The 
PD Clinic manages an IRB-approved research database consisting of approximately 1,000 patients 
who present with unilateral symptoms.  These patients consented for storage of their clinical history 
in the database and also consented to be contacted for future PD-related research studies.  Thus, 
information regarding side of disease onset (left vs. right) and date of PD diagnosis were archived in 
the database and available to study researchers during the recruitment process.  Clinical information 
was further verified by participants during the recruitment process and prior to the experimental 
session.     
Patients with right and left initial motor symptom onset were recruited into the following 
three PD progression groups:  
1) Early Unilateral Group – participants with early unilateral disease (defined as one year or 
less from date of diagnosis), with motor symptoms currently in the unilateral stage. 
2) Late Unilateral Group – participants with later unilateral disease (2-5 years from date of 
diagnosis), with motor symptoms still remaining in the unilateral stage. 
3) Bilateral Group – participants with later bilateral disease (a minimum of 5 but no more 
than 13 years since PD diagnosis), with motor symptoms beginning as unilateral but affecting 
both sides of the body at the time of neuropsychological testing. 
The Hoehn and Yahr (1967) index was used to determine the progression of PD motor dysfunction, 
and the Unified Parkinson’s Disease Rating Scale (UPDRS; Fahn & Elton, 1987) was utilized to 
determine motor severity.  Ratings on these measures were given to PD patients within 6 months of 
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the experimental session by a study collaborator (Kelly Lyons, Ph.D.) trained by the Movement 
Disorder’s Society to administer these scales.  Of note, current UPDRS and formal Hoehn and Yahr 
ratings could not be obtained for 3 PD participants; however, because their reported unilateral vs. 
bilateral status at the time of neuropsychological evaluation was confirmed by notes from their recent 
clinical visits, they were retained in the study.       
Patients in the two unilateral groups received a recent Hoehn and Yahr rating of Stage 1 
(unilateral disease), while all patients in the bilateral sample received a Hoehn and Yahr rating of 
Stage 2 (bilateral disease without impairment of balance).  See table below for an illustration of PD 
participants recruited in each group:        
             Side of Initial Motor Onset 
 
Symptoms of PD   Progression        Right               Left 
 
Unilateral (<1 year since diagnosis) 
 
 Early              
 
     10                 8 
Unilateral (2-5 years since diagnosis) 
 
Middle               8                  9 
Bilateral (> 5 years since diagnosis) Late             13                12 
 
 
The current study design permitted an examination of two different aspects of disease 
progression: illness duration (defined as years since receiving the diagnosis of PD) and disease stage 
(defined as the presence of unilateral vs. bilateral motor symptoms).  Current motor scores on the 
Unified Parkinson’s Disease Rating Scale (UPDRS; Fahn & Elton, 1987) were also reviewed for 
each patient to determine motor symptom severity.  The UPDRS motor scale examines the severity 
of speech, tremor, rigidity, deficits in facial expression, body bradykinesia, and other motor-related 
symptoms.  Although PD participants were not selected on the basis of motor symptom severity, 
UPDRS scores between right-sided onset and left-sided onset groups were also examined to 
determine if there were significant differences in scores within the same classified disease stage.            
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Healthy control sample.  Control participants were recruited from an IRB-approved 
research participant database consisting of healthy elderly adults and managed by staff at the Landon 
Center for Aging at the University of Kansas Medical Center (KUMC).  Participants in the healthy 
control database were prescreened by Landon Center staff and classified as healthy aging older 
adults.  However, participants were only included in the control sample if they met study inclusion 
criteria (described earlier), did not report current significant difficulty with activities of daily living, 
and obtained a score of 27 or higher on the Mini Mental Status Examination (MMSE).  
Procedures and Data Collection 
Individuals who indicated interest in the project were contacted via telephone to discuss the 
study and determine participant eligibility.  Those who met full study inclusion criteria were 
scheduled for a 2.5 – 3 hour session to undergo neuropsychological testing at the Landon Center for 
Aging at KUMC.   
Information regarding current medication regimen was recorded for all participants at the 
time of the neuropsychological evaluation.  With respect to medications, all PD participants were 
tested during their on state.  In order to reduce differences in dopaminergic modulation, time of day 
effects, and fatigue levels, most PD participants were scheduled for a morning session after their 
morning dose.  
All neuropsychological assessments were performed by a doctoral psychology student 
(Phuong Chau, M.A.) trained in the administration and scoring of the test battery, and supervised by 
a clinical neuropsychologist (Brenda Hanna-Pladdy, Ph.D.).  The research protocol was fully 
approved by the Institutional Review Board (IRB) of the University of Kansas Medical Center.  
Written informed consent was obtained for all participants at the beginning of the experimental 
session. 
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 Neuropsychological test battery 
 The following test battery was selected to evaluate a range of cognitive domains, and 
included tests that measure hemispheric specialization and frontal-striatal dysfunction. 
Screening Measures 
 Beck Depression Inventory Second Edition (BDI-II; Beck, Steer, & Brown, 1996).  The 
BDI-II is a 21-item self-report questionnaire that measures characteristic attitudes and symptoms of 
depression.  The BDI-II is one of the most widely used depression scales in clinical and research 
settings.  Scores range from 0 to 63, with higher scores indicating increased depressive 
symptomology.  Despite some concerns about the number of somatic items on the scale, the BDI-II 
appears to be a sensitive instrument to screen and measure the severity of depressive symptoms in 
patients with PD (Schrag et al., 2007). 
 Mini Mental Status Examination (MMSE; Folstein, Folstein, & McHugh, 1975). The 
MMSE is a brief cognitive measure often used in clinical and research settings as a quick screen for 
dementia.  Items include questions on orientation, attention, and memory.  Scores range from 0 to 30.        
American New Adult Reading Test (AMNART; Grober & Sliwinski, 1991).  Intellectual 
functioning was estimated using a quotient based on the reading of irregular words that are acquired 
through experience and education.  The AMNART shows a high correlation with the WAIS–R 
Verbal IQ Scale in nondemented patients (Grober & Sliwinski, 1991) and can be useful in generating 
a quick estimate of premorbid verbal intelligence.  
Tests of Language 
Boston Naming Test (BNT; Kaplan, Goodglass, & Weintraub, 1983). The BNT examines 
the ability to name pictured objects and evaluates for the presence of anomia.  A stimulus cue is 
given if the examinee clearly misperceives the picture, and a phonemic cue is given if the examinee 
is unable to correctly name the picture within 20 seconds.  The number of correct responses without 
phonemic prompts is recorded as the total correct score.  Scores range from 0 to 15.   
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Verbal Fluency Test from the Delis-Kaplan Executive Function Scale (D-KEFS; Delis, 
Kramer, & Kaplan, 2001).  Phonemic, semantic, and category switching tasks were administered.  In 
the phonemic fluency task, examinees are given three letters of the alphabet and asked to generate as 
many different words as they can beginning with the letter, within a one minute interval for each 
letter.  For the semantic fluency task, examinees are asked to quickly name different items from a 
single category (e.g., animals, boys’ names).  In the set switching condition, which is also frequently 
used as an executive function measure, participants alternate between naming different fruits and 
pieces of furniture.  Discrepant performances across tasks can offer information as to whether 
difficulty results from fluency or cognitive shifting demands.   
Visual-spatial Tasks 
Judgment of Line Orientation (JLO; Benton, Sivan, Hamsher, Varney, & Spreen, 1994).  
The JLO is commonly used to assess visuospatial perception and judgment.  For each item, 
examinees are shown a pair of lines on the top page and an array of 11 numbered lines on the bottom 
page.  The task is to match the orientation and position of the numbered lines below with the two 
target lines on the top page.  The shortened 15-item version of the JLO was used in the current study.  
Both lines must correctly be identified in each item in order to receive credit for that item.  Scores 
range from 0 to 15.        
Visual Form Discrimination Test (VFD; Benton, Hamsher, Varney, & Spreen, 1983).  The 
VFD is a 16-item test that examines visuoperceptual discrimination.  Examinees match a group of 
geometric figures from an array of choices.  Scores range from 0-16, and errors can be further 
examined as complete distortional errors or minor rotational or peripheral errors.        
Memory Tasks 
California Verbal Learning Test Short Form (CVLT-II-SF; Delis, Kramer, Kaplan, & 
Ober, 2000).  The CVLT-II-SF is a word-list learning task that provides information about 
acquisition, recall, retention, and retrieval of verbal information, as well as strategies used in 
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learning.  Participants are asked to learn a 9-item list of words over four consecutive trials and asked 
to recall the list once again immediately following an interference trial.  After a 20-minute delay, 
participants are asked to again recall words on the original list.   
Visual Reproduction I & II Tests from the Wechsler Memory Scale Third Edition (WMS-
III; Wechsler, 1997b).  The Visual Reproduction Test measures visuoconstructive ability and non-
verbal memory.  Examinees are presented with five line drawings and must draw each picture 
immediately after viewing the picture and again after a 20-30 minute delay.  Each item is scored 
according to standardized WMS-III criteria based on the presence, accuracy, and placement of 
various elements in the design.  Immediate recall, delayed recall, and copy trials were administered 
in the present study, with scores for each trial ranging from 0 to 66.     
Tests of Attention and Working Memory 
Digit Span from the Wechsler Adult Intelligence Scale Third Edition (WAIS-III; Wechsler, 
1997a).  Digit Span measures simple auditory attention by having subjects listen to a string of 
numbers and recite the numbers in a specified order (forwards or backwards).  Sequences of 
increasing length are administered for both the forwards and backwards conditions, and items correct 
across both conditions are summed for a total Digit Span score.  Possible score ranges are as follows: 
0-18 for Digit Span forwards, 0-16 for Digit Span backwards, and 0-34 for Digit Span total.     
Spatial Span (from the WMS-III; Wechsler, 1997b).  This test measures visuospatial 
attention.  In Spatial Span Forward, the examiner taps the blocks in a specified order, and the 
examinee taps the blocks following the same sequence.  In Spatial Span Backward, examinees tap the 
blocks in reverse order.  Items correct for both conditions are summed for a total Spatial Span score.  
Possible score ranges are as follows: 0-18 for Spatial Span forwards, 0-16 for Spatial Span 
backwards, and 0-34 for Spatial Span total.     
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Letter-Number Sequencing (from the WAIS-III; Wechsler, 1997a).  Letter-Number 
Sequencing measures auditory working memory and freedom from distractibility.  Participants are 
given a mixed string of numbers and letters and are asked to recite the letter-number combination in a 
specified order.  Responses are correct if there are no omissions of numbers or letters and if they are 
all recited in the specified sequence.  Scores range from 0 to 21.     
Trail Making Test (TMT, from the D-KEFS; Delis et al., 2001).  The D-KEFS Trail Making 
Test consists of a visual scanning task (Condition 1) and a series of four connect-the-dot tests.  These 
tests measure number sequencing, letter sequencing, number-letter sequencing, and motor speed 
(Conditions 2-5, respectively).  Although performance on the TMT is highly dependent on attention 
and speed, the number-letter sequencing task (Condition 4) is considered to involve an executive 
component due to its set shifting demands.  The multiple conditions further allow determination of 
whether poor test performance is attributable to visual search problems, sequencing speed, motoric 
speed, or the executive demands of the test.  Higher scores indicate worse performance.         
Tests of Executive Function and Reasoning  
Wisconsin Card Sorting Test (WCST-64; Kongs, Thompson, Iverson, & Heaton, 2005).  
The WCST examines abstract reasoning, concept generation, and perseverative responding.  This 
task involves the sorting of cards according to one of three categories: color, number of elements, or 
shape.  Examinees are never told the correct sorting category but only whether their responses are 
correct or incorrect.  The sorting category changes unexpectedly when the examinee has figured out a 
particular solution.  A computerized and shortened (64 cards) version of the WCST was used for this 
study.  Test indices retained for analysis included the number of categories reached (with possible 
scores ranging from 0 to 5) and the number of perseverative errors committed.        
Go-NoGo Test.  A computerized Go-NoGo Test was developed for the current study.  Go-
NoGo paradigms examine response inhibition and impulsivity by requiring examinees to inhibit 
preprotent behaviors that were practiced and rehearsed in earlier segments of the task.  There were 
 
 21 
two main conditions in our Go-NoGo paradigm.  In the first condition, participants were rapidly 
presented with one of two visual stimuli on the computer screen: either one red square or two red 
squares.  Auditory stimuli accompanied each visual stimulus – one short beep occurred during each 
presentation of the single red square, and two short beeps during each presentation of two red 
squares.  Examinees were asked to hit the space bar twice if they saw one red square, and to hit the 
space bar once if they saw two red squares.  In the second condition, participants were again rapidly 
presented with the same stimuli as in the first condition.  However, this time, they were instructed to 
hit the space bar twice when they saw one red square, and to inhibit any response each time they saw 
two red squares (the “no go” stimulus).  Test indices for analysis included average reaction time per 
item and percentage of correct and incorrect responses in the second condition.          
Sensorimotor Tasks 
Subjects were asked to perform two speeded sensorimotor tasks using first their dominant 
and then their nondominant hand.  Performance was scored separately for the right and left hand. 
Finger Oscillation Test (Reitan & Wolfson, 1985).  The Finger Oscillation Test, also known 
as Finger Tapping Test, was used to measure the speed of open looped movements.  Participants 
place their hand on a finger tapping board (manufactured by the Lafayette Company) and are asked 
to tap as fast as they can.  The apparatus records the number of taps, and the score is the mean 
number of taps in five 10 second trials for each hand. 
Grooved Pegboard Test (Reitan & Wolfson, 1985).  The Grooved Pegboard Test (also a 
Lafayette instrument) was used to assess closed loop movements for each hand.  Participants rotate 
small grooved pegs and place them into a board filled with keyhole-shaped holes in various 
orientations.  Test indices include task completion time and number of pegs dropped during the test.  
Higher scores (on either test indice) indicate worse performance.    
The neuropsychological tests within the five cognitive domains (language, visuospatial, 
attention/working memory, memory, executive function) were used in the main analyses.  The BDI-
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II, MMSE, and AMNART were included in the battery as screening measures and were analyzed for 
descriptive purposes only.  Sensorimotor tests were also included in the battery to examine the 
relationship between laterality of motor symptom onset and current asymmetries in fine motor skills.  
However, because assessment of fine motor skills was not a main focus of the study, performance on 
these tests was not included in the main analyses. 
Study Design 
Two independent variables (side of initial motor symptom onset and disease progression) 
were used as grouping variables in this study.  As indicated previously, side of disease onset was 
established by classifying patients into groups based on the lateralization of their motor symptoms at 
the time of disease onset (left and right).  Patients were assigned to groups based on their current 
disease progression (early unilateral, late unilateral, or late bilateral).   
In order to examine hypothesis # 1 of a relationship between lateralization of motor and 
cognitive profiles for patients in the early stages of the disease, the following neuropsychological 
tests in the battery were evaluated:  
• Tests of left hemisphere function: Boston Naming Test, Phonemic Fluency (Part I of the D-
KEFS Verbal Fluency Test), Category Fluency (Part II of the D-KEFS Verbal Fluency Test), 
Digit Span, Letter Number Sequencing, California Verbal Learning Test Second Edition 
(CVLT-II).     
• Tests of right hemisphere function: Spatial Span, Visual Form Discrimination Test, Judgment 
of Line Orientation, Visual Reproduction I & II, Visual Search (Condition 1) of  D-KEFS 
Trail Making Test.   
Study hypotheses #2 and #3 pertain to the performance of PD patients and healthy  
controls across multiple general domains of cognitive functioning.  Because right-left hemispheric 
differences are less relevant for these analyses, the neuropsychological tests were regrouped into 
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cognitive functions that are considered to be more frontal-striatal in comparison  to those that are 
believed to involve more medial temporal lobe and posterior cortical brain regions.  These groupings 
are as follows: 
• Frontal-executive domain: Go-NoGo Test, Wisconsin Card Sorting Test, D-KEFS switching 
conditions (of Trail Making and Verbal Fluency tests). 
• Attention/working memory: Digit Span forwards, Digit Span backwards, Spatial Span 
forwards, Spatial Span backwards, Letter Number Sequencing.  
• Language: Boston Naming Test, D-KEFS Verbal Fluency Test (phonemic and semantic tasks 
only). 
• Visuospatial skills: Judgment of Line Orientation, Visual Form Discrimination Test, Visual 
Search (Condition 1) of D-KEFS Trail Making Test. 
• Information acquisition/memory encoding: relevant information acquisition measures from 
the CVLT-II-SF and Visual Reproduction. 
• Memory retention: relevant memory retention indices from the CVLT-II-SF and Visual 
Reproduction.    
 To review, it was expected that PD patients in the (early and late) unilateral stages would 
display attentional, frontal-executive, and memory encoding deficits, consistent with dopamine 
depletion as the primary pathology during early disease stages.  Also, we predicted that the severity 
of impairment would increase with years of progression.  That is, while the late unilateral group may 
be impaired relative to controls, it may be the case that early unilateral patients may be at too early a 
disease stage to detect significant changes.  Finally, we expected bilateral patients to display more 
severe attentional and frontal-executive deficits, as well as additional deficits suggestive of greater 
cerebral involvement, including language, visuospatial, and memory retention deficits. 
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Results 
Preliminary Analyses 
Demographic and clinical characteristics of PD and control groups.  Demographic and 
clinical data for the PD and control participants, including group means and standard deviations, are 
presented in Table 1.  Sixty individuals (43 males, 17 females) comprised the PD sample, and there 
were 20 healthy controls (13 males, 7 females).  The PD sample ranged from 51 to 77 years in age, 
and the control sample ranged from 51 to 76 years.  There were no significant differences between 
PD and control groups with respect to current age (t (2,78) = 1.07, p =.29), years of education ( t 
(2,78) = 1.00, p = .32), or gender ratio (X² (1, N = 80) = .32, p = .57).  The PD group was found to 
exhibit more depressive symptoms (t (2,78) = 3.19, p < .01), lower MMSE scores (t (2,78) = 3.69, p 
< .01), and lower AMNART scores (t (2,78) = 3.17, p < .01) compared to controls.  Since depressive 
symptomology and lowered mental status are known features of PD that may be closely connected to 
the disease process in PD (Frisina, Borod, Foldi, & Tenenbaum, 2008), they were not used as 
covariates in subsequent analyses.  Despite its common use to achieve an estimate of premorbid 
intellectual function, the AMNART was also not used as a covariate in subsequent analyses due to its 
likely relationship to current cognitive decline (Taylor, Salmon, Rice, Bondi, Hill, et al., 1996).  
Thus, BDI-II, MMSE, and AMNART scores are reported for descriptive purposes, but were not used 
in further analyses comparing the neuropsychological performance of controls and PD groups.     
Demographic and clinical characteristics of the different PD groups.  Data comparing 
demographic and clinical characteristics between the right- and left-sided onset PD groups are 
presented in Table 2.  No significant differences were found between these two PD groups on age (t 
(2,58) = 1.20, p =.24), years of education (t (2,58) = .11, p = .91), or gender distribution (X² (1,60) = 
1.05, p = .31).  The groups also did not differ in clinical characteristics such as age of disease onset (t 
(2,58) = 1.62, p = .11), disease duration (t (2,58) = 1.10, p = .28), or total UPDRS scores (t (2,58) = 
.58, p = .57).  The left-sided onset group had been taking PD medications for a slightly longer period 
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of time on average (mean = 5.0 years, SD = 4.3) than the right-sided onset group (mean = 3.4 years, 
SD = 2.4), but this difference was not statistically significant, t (2,58) = 1.88, p = .07.       
Table 3 presents data on characteristics of the PD groups at different disease levels of disease 
progression (early unilateral, late unilateral, and bilateral stages).  These three groups did not differ in 
demographic characteristics such as current age (F (2,57) = .59, p = .56), education (F (2,57) = .01, p 
= .99), or gender ratio (X² (1,60) = 1.41, p = .49).  There were also no significant group differences in 
BDI-II (F (2,57) = 1.66, p = .20), MMSE (F (2,57) = .80, p = .46), or AMNART scores (F (2,57) = 
1.32, p = .28).  The groups significantly varied in PD characteristics such as years since initial 
diagnosis (F (2,57) = 57.87, p < .001), years since initial symptom onset (F (2,57) = 32.68, p < .001), 
and UPDRS score (F (2,54) = 16.14, p < .001) confirming appropriate characteristics for group 
assignment.  Since PD groups were balanced with respect to current age, the trend was for patients 
with longer disease severity to display younger ages at initial diagnosis, although group differences 
in age at disease onset did not achieve statistical significance (F (2,57) = 3.12, p = .052). 
Table 4 further presents demographic and clinical characteristics of the different PD groups 
by both side of initial symptom onset and current disease stage.  Similar to above results, these six 
groups did not differ in demographic characteristics such as current age (F (5,54) = .61, p = .72), age 
at disease onset (F (5,54) = 1.90, p = .11), education (F (5,54) = .77, p = .60), or gender ratio, (X² 
(5,60) = 3.63, p = .73).  They also did not significantly differ in BDI-II (F (5, 54) = 1.50, p = .19), 
MMSE (F (5,54) = .65, p = .69), or AMNART scores (F (5,54) = 1.45, p = .21).  The six groups 
varied in PD characteristics such as years since initial diagnosis (F (5,54) = 27.86, p < .001), years 
since initial symptom onset (F (5,54) = 14.90, p < .001), number of years on PD medications (F (5, 
54) = 16.1, p = <.001), and total UPDRS score (F (5,54) = 6.95, p < .001), with the direction of 
scores generally consistent with group assignment.  
Medications.  A qualitative analysis was performed to identify if there were differences 
between PD groups with respect to the types of medications taken at the time of the 
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neuropsychological evaluation.  This information was examined in order to determine whether 
differences on the cognitive measures could potentially be accounted for by differences in treatment 
regimens between PD groups.  The majority of PD participants (91.7%) were taking either a 
dopamine precursor (e.g., carbidopa-levodopa) or a dopaminergic agonist (e.g., ropinirole, 
pramipexole) medication, occasionally in combination with other drugs (such as COMT-I, MAOI, or 
anticholinergic drugs).  Approximately 25% of the PD group was also taking an antidepressant 
and/or antianxiety medication.  No strong trends were noted in medication regimen amongst the 
different PD groups.  Numbers and percentages of PD participants prescribed each class of 
medication are presented in Tables 5 and 6.       
Data preparation  
Raw scores for all neuropsychological test indices were used in the analyses.  Although 
normed scores were also available for use (age-corrected scores with published normative data 
serving as references, as well as computation of z scores for all participants based on the means and 
standard deviations of the control sample), raw data were employed for ease of presentation since 
similar patterns emerged regardless of whether raw or normed data were used.     
Statistical assumptions for multivariate analysis of variance (MANOVA) were evaluated, 
including assumptions of normality, linearity, homoscedasticity, and the absence of univariate or 
multi-cell outliers (Tabachnik & Fidell, 2001).  There was only one significant univariate outlier, 
which was omitted from further analyses.  Some of the individual variables within groups had 
significant departures from normality as assessed by the Shapiro Wilk test.  Because MANOVA and 
ANOVA tend to be robust to relatively minor violations of this assumption, results were reported 
without data transformation of the select variables.  For the multiple MANOVAs performed in this 
study, Box’s Test was significant for several, meaning that the covariance matrices significantly 
differed across the dependent variables for those analyses.  For those select MANOVAs, the 
generally more conservative Pillai’s Trace criterion was used rather than Wilks’ Lambda, since the 
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former tends to be more robust to departures from the homoscedasticity assumption in the evaluation 
of multivariate effects.  Dependent variables in each MANOVA were grouped according to a priori 
assumptions of the underlying constructs they are measuring.  Correlations between DVs in each 
MANOVA were also examined to ensure they were measuring similar constructs, and were 
moderately but not too highly correlated with each other.   
Significant MANOVAs were followed up with univariate tests, and significant ANOVAs 
were further examined with post-hoc comparisons.  A few neuropsychological variables had unequal 
variances between groups based on Levene’s Test; however, results were examined since ANOVA 
also tends to be quite robust to relatively minor violations of the homogeneity of variance 
assumption.   
Main analyses  
The relationship between side of initial motor symptom onset and current disease stage 
on right and left hemisphere neuropsychological measures.  One of the primary aims of this study 
was to evaluate whether initial laterality of motor symptoms in PD would predict cognitive profiles at 
different stages of disease progression.  In order to evaluate this, two 3 X 2 MANOVAs were 
calculated (one for left hemisphere measures, and the second for the right hemisphere measures), 
with disease progression group (early unilateral, later unilateral, later bilateral) and side of motor 
symptom onset (right or left) as the independent variables.  If findings are congruent with our 
hypothesis that lateralization of cognitive deficits in PD vary as a function of disease progression 
(hypothesis #1), a significant interaction would be expected between side of motor symptom onset 
and disease progression in each of these two MANOVAs.  However, the multivariate interaction was 
not significant for either the left hemisphere measures (Wilks’ Lambda = .75, F (14,96) = 1.07, p 
=.39) or the right hemisphere measures (Pillai’s Trace = .24, F (12,100) = 1.15, p = .33).  For these 
sets of analyses, all multivariate main effects were also nonsignificant.  Side of initial symptom 
motor onset was not found to be significantly related to the left hemisphere measures (Wilks’ 
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Lambda = .85, F (7,48) = 1.21, p = .32), and disease progression was also nonsignificant as a main 
effect for the combined left hemisphere measures (Wilks’ Lambda = .81, F (14,96) = .75, p = .72).  
For the combined right hemisphere measures, neither the side of initial symptom onset (Pillai’s Trace 
= .08, F (6,49) = .68, p = .67) nor disease progression (Pillai’s Trace = .16, F (12,100) = .74, p = .71) 
was significant.  Table 7 lists the means and standard deviations of the PD groups (by disease stage 
and side of initial motor symptom onset) on all left and right hemisphere measures.  
Comparisons between the controls and PD groups at different levels of disease 
progression.  To establish whether PD patients display cognitive dysfunction relative to healthy 
controls, one way MANOVAs were performed to compare the four groups (controls, early unilateral 
group, later unilateral group, and bilateral group) on each of the six domains of cognitive function 
(frontal-executive, attention/working memory, language, visuospatial ability, memory encoding, and 
memory retention).  Table 8 lists means and standard deviations of all groups on the test indices 
comprising the different cognitive domains, as well as p values for all multivariate and univariate 
analyses of group differences.      
The multivariate effect was nonsignificant for the frontal-executive measures (Pillai’s Trace 
= .26, F (12,216) = 1.69, p = .071), although it came close to reaching statistical significance.  The 
multivariate effect was also nonsignificant for separate MANOVAs conducted for measures in the 
attention/working memory (Wilks’ Lambda = .81, F (15,199) = 1.04, p = .42), language (Pillai’s 
Trace = .14, F (9,228) = 1.22, p = .29), and visuospatial (Pillai’s Trace = .14, F (9,228) = 1.25, p = 
.27) domains.  Univariate analyses will thus not be examined for individual measures in these 
cognitive domains, although group means and standard deviations for these measures, as well as p 
values of univariate analyses, are presented in Table 7.   
The MANOVAs performed to evaluate group differences on both the information encoding 
and retention aspects of memory were significant.  The groups differed on the combined memory 
encoding measures, Wilks Lambda = .75, F (6,150) = 3.90, p = .001.  Follow-up ANOVAs with 
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these measures revealed a significant difference on CVLT-II learning (F (3,76) = 7.61, p < .001), but 
not for Visual Reproduction learning (F (3,76) = 2.43, p = .072).  Bonferroni post-hoc comparisons 
for CVLT-II learning yielded only one significant pairwise difference, between the controls and 
bilateral group (p < .001). 
The groups also differed on the combined memory retention measures, Wilks Lambda = .76, 
F (6,150) = 3.73, p = .002.  A follow-up univariate analysis revealed a significant overall group 
difference on CVLT-II delayed performance (F (3,76) = 6.88, p < .001), and paired comparisons 
revealed only a significant difference between controls and the bilateral group (p < .001).  The 
follow-up univariate analysis applied to Visual Reproduction delayed performance was not 
significant, but came close to significance, F (3,76) = 2.67, p = .053.   
Examination of a priori hypotheses concerning specific group differences.  In order to 
improve detection of hypothesized differences between groups, a series of planned comparisons were 
conducted to investigate if there were significant predicted differences not previously revealed by the 
earlier analyses.  Tables 9 and 10 illustrate results of all planned comparisons examined and their p 
values (one-tailed, since hypotheses were all directional) if significant.  All planned contrasts were 
examined for statistical significance using the Bonferroni-Holm procedure to control for Type I error 
(Abdi, 2010).                       
Table 9 presents results of planned comparisons that examine the performance of healthy 
controls and 6 PD groups on designated right and left hemisphere measures, in order to evaluate the 
prediction that lateralized deficits are associated only with unilateral disease (hypothesis #1).  These 
contrasts included comparisons between controls and each of the 6 PD groups, as well as those 
examining differences between right- and left-sided onset groups within each of the three disease 
progression stages.  On the left hemisphere measures, controls outperformed the left-sided onset 
early unilateral group on CVLT-II learning, and no other differences were observed between controls 
and the right- and left-sided onset early unilateral groups.  The right-sided onset late unilateral group 
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were more impaired relative to controls on category fluency and CVLT-II learning, and no other 
comparisons were significant between controls and the two late unilateral groups on the left 
hemisphere measures.  The right-sided onset bilateral group demonstrated significantly weaker 
performances relative to controls on letter fluency, category fluency, WAIS-III letter number 
sequencing, and CVLT-II learning and memory retention.  The left-sided onset bilateral were 
impaired relative to controls on CVLT-II learning and memory retention.  On the left hemisphere 
measures, the right-sided onset bilateral group were also more impaired than the left-sided bilateral 
onset group on WAIS-III letter number sequencing; otherwise, no other contrasts were significant 
that examined right- and left-sided onset group differences within the same disease stage.  For all 
planned contrasts with the right hemisphere measures, the only comparisons that were significant 
were between the controls and right-sided onset bilateral group on D-KEFS visual search speed and 
Visual Reproduction II.                    
Table 10 presents findings for the remainder of the planned comparisons, which compare the 
performance of controls and PD groups by disease stage.  The first of these contrasts examined the 
performance of healthy controls and the unilateral patients groups in order to evaluate the prediction 
that unilateral PD disease would be associated with impairment in the frontal-executive, 
attention/working memory, and memory encoding domains (hypothesis #2a).  For these comparisons, 
select planned contrasts (healthy controls vs. early unilateral, and healthy controls vs. late unilateral) 
were examined for individual neuropsychological measures in each of these three domains.  After 
implementing Bonferroni-Holm corrections, the following contrasts were statistically significant: 
controls outperformed the early and late unilateral groups on Digit Span backwards, and controls also 
outperformed both groups on verbal memory encoding.           
The next group of planned comparisons evaluated differences between the early unilateral 
and late unilateral groups to examine the prediction that the late unilateral group would show more 
severe impairment across measures of frontal-executive function, attention/working memory, and 
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memory encoding (hypothesis #2b).  For this comparison, contrasts between the early and late 
unilateral groups were examined for all measures within these domains.   However, none of these 
contrasts were found to be significant.        
The final set of planned comparisons examined the hypothesis that PD patients in the 
bilateral disease stage would show impairment across all cognitive domains as compared to controls 
and patients in the earliest stages of PD (hypothesis #3).  The bilateral group was compared to 
controls and the unilateral group on all measures in which Bonferroni post-hoc comparisons did not 
already reveal significant differences.  In the frontal executive domain, the bilateral group performed 
significantly worse than controls on all four measures, and worse than the early unilateral group on 
DKEFS Trails switching only.  For attention/working memory measures, the bilateral group was 
more impaired than the controls on Digit Span backwards.  The bilateral group and controls came 
close to being significantly different on Letter Number Sequencing and Spatial Span backwards, but 
these contrasts were not significant after applying Bonferroni-Holm adjustments.  No significant 
differences were observed between the bilateral and early unilateral groups on attention/working 
memory measures.  In the language domain, controls outperformed the bilateral group on DKEFS 
Letter Fluency and DKEFS Semantic Fluency, and no significant differences were observed between 
the bilateral and early unilateral groups.  For the visuospatial measures, controls significantly 
outperformed the bilateral group on the JLO only, and no other planned contrasts were significant.  
In the memory encoding domain, as reportedly previously Bonferroni post-hoc comparisons had 
revealed significant differences between the bilateral group and controls on verbal information 
encoding (CVLT-II total on learning trials).  Planned contrasts additionally revealed a significant 
difference between the bilateral group and controls on nonverbal information encoding (Visual 
Reproduction I), as well as differences between the bilateral and the unilateral groups on verbal 
information encoding.  The planned contrast applied to bilateral and unilateral groups on nonverbal 
information encoding came close to significance at p = .046.  Within the memory retention domain, 
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post-hoc comparisons had earlier revealed differences between the bilateral group and controls on 
verbal memory retention (CVLT-II long delay performance).  Planned contrasts between groups in 
the memory retention domain additionally revealed the following: significant differences between the 
bilateral group and controls on nonverbal memory retention (Visual Reproduction II), and significant 
differences between the bilateral and early unilateral groups on both verbal memory retention and 
nonverbal memory retention. 
Additional comparisons between groups.  Table 11 presents results of additional contrasts 
that were conducted, in order to further explore group differences on cognitive measures not 
examined in the planned comparisons.  P values were evaluated for significance at the two-tailed 
level and after implementation of Bonferroni-Holm corrections.  Results of these comparisons 
showed that the right-sided onset bilateral group performed worse than controls on the following 
additional measures: D-KEFS trails switching, Go NoGo contrasting motor condition, Digit Span 
backwards, and Spatial Span backwards.  The right-sided onset bilateral group also performed worse 
than the left-sided onset group on the Go NoGo contrasting motor task.  No other contrasts were 
significant in these additional comparisons. 
Supplementary Analyses 
 Discriminant function analyses.  MANOVAs were followed with discriminant function 
analyses to evaluate the accuracy of the neuropsychological test measures in classifying different 
groups.  The neuropsychological test indices that were used as predictors in these analyses were 
previously found to be significant either in the MANOVAs and follow-up ANOVAs or in the 
planned comparisons.  Three discriminant function analyses were performed on the data.  The first 
examined whether select test indices were effective in differentiating PD patients from controls in 
our sample.  The second was performed to examine how accurately the predictor variables could 
group PD participants according to their level of disease progression (early unilateral, late unilateral, 
or late bilateral).  The final discriminant function analysis investigated whether cognitive measures 
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could differentiate between PD patients with left-sided symptom onset vs. those with right-sided 
symptom onset.   
 For the first discriminant function analysis, there were two grouping variables (patient vs. 
control status) and the predictors entered into the model included the following: D-KEFS verbal 
switching, D-KEFS trails switching, WCST categories matched, Go NoGo contrasting motor 
condition, Digit Span backwards, Letter Number Sequencing, D-KEFS letter fluency, D-KEFS 
category fluency, Judgment of Line Orientation, CVLT-II learning total, CVLT-II delayed recall 
performance, Visual Reproduction I, and Visual Reproduction II.  For this discriminant function 
analysis, a Wilks’ Lambda of .68 was statistically significant (p = .015) and suggested that the model 
adequately discriminated between the control and patient groups.  All predictor variables 
significantly discriminated between the two groups at least at the p < .05 level, with the exception of 
D-KEFS trails switching (p = .062), WCST categories sorted (p = .069), Letter- Number Sequencing 
(p = .083), and Visual Reproduction I (p = .24).  The direct solution entering both variables 
simultaneously produced 76.3% correct classifications, with 7.5% false positives, and 16.2% false 
negatives.  The classification matrix is presented in Table 12.   
The second discriminant function analysis had three grouping variables (early unilateral, late 
unilateral, and bilateral) and included the following predictor variables: D-KEFS verbal switching, 
D-KEFS trails switching, WCST categories matched, Go NoGo contrasting motor condition, Digit 
Span backwards, D-KEFS letter fluency, D-KEFS category fluency, CVLT-II learning total, CVLT-
II delayed recall performance, Visual Reproduction I, and Visual Reproduction II.  However, these 
predictors were less accurate in grouping PD participants according to their level of disease 
progression, as results were nonsignificant (Wilks’ Lambda = .67, p = .56), and only 51.7% of PD 
patients were correctly classified in their respective disease stage groups. 
The final discriminant function analysis explored whether measures previously significant in 
the planned comparisons could adequately discriminate between the left- and right-sided onset PD 
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groups.  The following predictor variables were entered simultaneously in the direct solution: D-
KEFS letter fluency, D-KEFS category fluency, Letter-Number Sequencing, CVLT-II learning, 
CVLT-II memory retention, D-KEFS visual search, and Visual Reproduction II.  Results were 
nonsignificant (Wilks’ Lambda =  .83, p = .17), with 63.3% of PD patients correctly classified. 
 Group differences on fine motor skills.  Table 13 displays raw data means and standard 
deviations on the motor tasks for the PD groups.  In order to evaluate group performances on fine 
motor measures, a 3 X 2 MANOVA was performed, with disease progression group (early unilateral, 
later unilateral, later bilateral) and side of motor symptom onset (right or left) as the independent 
variables, and right- and left-handed scores on the Grooved Pegboard and Finger Tapping tasks 
serving as the dependent variables.  The multivariate interaction was not significant (Wilks’ Lambda 
= .76, F (8,94) = 1.75, p =.10), and the multivariate main effect for current disease stage was also 
nonsignificant (Wilks’ Lambda = .87, F (8,94), p = .58).  However, there was a multivariate main 
effect for initial laterality, as side of initial symptom motor onset was found to be significantly 
related to the combined motor DV’s (Wilks’ Lambda = .56, F (4,47) = 9.37, p < .001).  Further 
investigation with univariate analyses revealed that the left-side onset group performed worse than 
the right-side onset group on both of the left-handed measures (Grooved Pegboard left hand: F (1,50) 
= 5.51, p = .02, Finger Tapping left hand: F (1,50) = 17.14, p < .001).  The two groups did not differ 
in their scores when performing on right-handed measures.   
Motor asymmetry scores were computed by the formula (right hand performance – left hand 
performance / right hand performance).  Higher asymmetry scores indicate superior performance on 
the right dominant hand, whereas lower asymmetry scores above zero indicate less skill superiority 
on the right hand.  Scores that are in the negative range reflect nondominant (left hand) skill 
superiority on the specific motor measure, as all participants in the study were right hand dominant.  
The sign for the computed asymmetry score from Grooved Pegboard was reversed (e.g., if a (R-L)/R 
score was .17, it then became a -.17) in order to maintain consistency across the motor measures.  To 
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examine whether patient groups display differences in observed asymmetries on motor skills, a 3 X 2 
MANOVA was performed with disease progression and side of motor symptom onset as the 
independent variables, and with motor asymmetry scores on the Finger Tapping and Grooved 
Pegboard tests serving as the dependent variables.  A significant interaction between initial side of 
motor symptom onset and disease progression was found for combined motor asymmetry (Wilks’ 
Lambda = .74, F (4,98) = 4.00, p =.005).  Follow-up ANOVAs reveal that the interaction was 
significant for both the Finger Tapping and Grooved Pegboard tasks.  Figure 1 illustrates this 
interaction, which was similar for both motor tasks.  Since the multivariate and univariate 
interactions between independent variables were significant, multivariate and univariate main effects 
were not examined.       
Discussion  
 This study examined the effects of initial side of motor symptom onset and current disease 
stage on cognition in PD.  Previous research examining the effects of motor symptom laterality on 
cognition has yielded mixed results; thus, the aim of the current investigation was to examine 
whether disease severity/duration could explain some of the heterogeneity of past studies and clarify 
the role of initial side of symptom onset in influencing later cognitive profiles. Present findings 
revealed a) some support for a significant relationship between initial laterality of motor symptoms 
and later cognitive pattern, and b) cognitive deficits in PD consistent with hypothesized effects of 
disease progression.  Findings are further discussed below.           
 Initial laterality of motor symptoms and cognition in PD 
Side of motor symptom onset in PD is believed to be an important clinical and 
neuropathological factor of the disease.  Motor symptoms in PD typically begin on one side of the 
body, and patients whose symptoms begin on the left side of the body have greater nigrostriatal 
pathology in the right hemisphere whereas those with right side symptom onset have greater left 
hemisphere pathology (Kempster et al., 1989; Nahmias et al., 1985).  Therefore, it was predicted 
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(hypothesis #1) that initial side of motor symptom onset would be associated with lateralized 
cognitive deficits only during the unilateral disease stage, and that lateralized deficits would not be 
observed in the bilateral disease stage.   
The present dataset supported some aspects of our laterality hypothesis.  In this study, 
individuals with right-sided onset unilateral disease demonstrated impaired performance relative to 
controls on some left hemisphere measures (i.e., category fluency and verbal memory encoding) that 
were not observed in the left-sided onset unilateral group, which is consistent with hypothesized 
lateralized deficits during unilateral disease in PD.  Although the left-sided onset unilateral group did 
not significantly differ from controls or the right-sided onset unilateral group on any of the right 
hemisphere measures, the left early unilateral group did perform worse than controls on one of the 
left hemisphere measures (verbal learning/encoding).  In the bilateral stage, those with initial right-
sided motor symptoms demonstrated more pervasive impairment on left hemisphere measures (which 
extended beyond category fluency and verbal memory encoding to also include letter fluency, a task 
of auditory working memory, and verbal memory retention) and some right hemisphere measures 
(visual search and nonverbal learning/encoding), while the left-sided bilateral onset group were 
impaired relative to controls on verbal learning/encoding and retention.   
Our results are consistent with some previous studies (Bentin et al., 1981; Blonder et al., 
1989; Starkstein et al., 1987) suggesting a possible relationship between initial side of motor 
symptom onset and later lateralized cognitive deficits.  In general, the right-sided onset group 
showed greater impairment on left hemisphere measures than the left-sided onset group, and 
particularly on tasks with a strong executive component.  Somewhat contrary to our predictions, the 
lateralizing pattern was stronger for the right bilateral group than for the right unilateral group.  Upon 
further reflection, this may not be entirely surprising, since unilateral disease is associated with 
deficits on primarily executive tasks, and executive dysfunction does not seem to consistently 
demonstrate a strong lateralizing pattern.   
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Another interesting finding was that the right bilateral group seemed to show greater 
cognitive impairment than all other groups (and more so than the left bilateral group) on both left and 
right hemisphere measures.  Given that the groups were relatively balanced with respect to relevant 
demographic and PD characteristics, this could suggest that right-sided motor symptom onset is 
associated with more rapid cognitive decline than left-sided motor symptom onset, which has been 
posited by previous researchers (Williams et al., 2007).  Alternatively, this finding may be an artifact 
of our small sample size. 
Other past investigations have also documented a relationship between right-sided motor 
symptoms and diminished performance on tests of left hemisphere function, with no observed 
impairments for the left-sided individuals on tasks assessing right hemisphere function (Huber et al., 
1992; Spicer et al., 1988).  One distinct possibility for current null results with the right hemisphere 
measures is that the study simply lacked statistical power to detect significant group differences due 
to sample size.  Some of these measures demonstrated a pattern consistent with the study’s 
hypothesis regarding lateralization of deficits, but results did not achieve overall statistical 
significance.  It is possible that the cognitive tasks utilized in our study (as well as previous studies 
with similar findings) were not as sensitive in detecting right hemisphere pathology.  In any case, 
results suggest further exploration in this area.  Future replication of this study with a larger sample 
may sufficiently increase statistical power to fully detect hypothesized differences.         
Disease progression and cognition in PD  
 The current study also examined cognitive changes that occur as the disease progresses from 
the earliest stage after onset of clinical symptoms to later in the disease course when motor 
symptoms have become bilateral.  Differences in neuropsychological performance were examined 
between age and education matched controls and the following three PD groups: early unilateral (< 1 
year post diagnosis), late unilateral (2-5 years post diagnosis) and bilateral (over 5 years post 
diagnosis). 
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Cognitive deficits during early unilateral stages.  It was predicted that PD in the unilateral 
stage would be associated with impairments in the frontal-executive, attention/working memory, and 
memory encoding domains (hypothesis #2a).  Results were significant for differences between 
controls and the unilateral groups on two measures within these domains:  Digit Span backwards, and 
CVLT information encoding.  Although Digit Span backwards and CVLT list learning were not 
grouped within the frontal-executive domain, they can certainly be construed as executive abilities 
that involve efficiency in planning and simultaneous operation of a number of different cognitive 
processes.  The Digit Span backwards trial involves internal control of attention, holding information 
in temporary storage for manipulation, and then reciting numbers in the reverse order that they were 
presented.  And in order to effectively learn a list of auditory presented words, an efficient 
organizational strategy to aid encoding is necessary.  Results on some other measures came close but 
were not statistically significant.  These findings suggest that even at the earliest stage of PD, some 
changes can be observed in cognitive abilities that reflect frontal-striatal dysfunction.  These results 
are consistent with the past findings suggesting a relationship between early stage PD and 
impairments in planning and working memory (Cools et al., 2001, Duke & Kaszniak, 2000; 
Muslimovic et al., 2005; Taylor et al., 1986; Zgaljardic et al., 2006), and suggest that signs of frontal-
striatal circuitry dysfunction may be observed even within one year or less of receiving the PD 
diagnosis.      
 It was also predicted that the progression from early to late unilateral disease would be 
associated with increased deficits on measures sensitive to frontal-striatal dysfunction (hypothesis 
#2b).  Although there was a trend for lower scores in the late unilateral group, no significant 
differences were found between the two unilateral groups on any of the measures examining frontal-
executive, attention/working memory, and memory encoding.   These nonsignificant findings may be 
at least partly due to the study’s methodology and selection criteria.  Average disease duration for the 
early unilateral group was .8 years, and average disease duration for the late unilateral group was 3.7 
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years.  Thus, it may be the case that differences in disease duration between the two groups were not 
sufficiently varied in detect changes consistent with disease progression.        
 Cognitive deficits associated with later bilateral disease.  Another study prediction was 
that PD patients in the bilateral disease stage with disease duration of at least 5 years would exhibit 
more global cognitive deficits than patients in the earlier unilateral stages, consistent with 
hypothesized involvement of additional non-dopaminergic pathology later in the disease course 
(hypothesis #3).  Our results suggest that by the time PD progresses to the bilateral stage and beyond 
5 years, deficits are observed in many cognitive domains, including frontal-executive function, 
attention/working memory, memory encoding, language, visuospatial skills, and memory retention 
ability.   
 Patients in the bilateral disease stage were more impaired than controls on all four measures 
of frontal-executive function (WCST, Go NoGo, Verbal Fluency switching, and Letter-Number 
switching tasks), one measure of attention/working memory (Digit Span backwards score), and both 
verbal and nonverbal information encoding (CVLT-II and Visual Reproduction learning).  These 
executive and related deficits are certainly more pervasive than the changes observed in patients with 
unilateral disease, who displayed deficits compared to controls on only two of these measures (Digit 
Span backwards and CVLT-II learning).  Notably, the bilateral group was also more impaired 
relative to the early unilateral group on select measures (verbal and nonverbal information encoding 
and D-KEFS Letter-Number switching task).  The increased severity of executive impairments in the 
bilateral stage likely mirrors the progression of frontal-striatal pathology in PD over time.  Also, 
increased executive impairments could also be due to additional cortical pathology at later stages that 
are believed to be part of the disease progression in PD (Braak et al., 2003; Braak & Braak, 2000) or 
due to comorbid pathology in later diseases that are unrelated to PD such as Alzheimer’s disease or 
disruption of non-dopaminergic neuronal systems (Dubois & Pillon, 1992; Emre, 2003; Galvin, 
2006; Jellinger, 2001; Zdaljardic et al., 2004).    
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The bilateral group also demonstrated impairments in language and visuospatial ability.  The 
literature on language deficits in PD has been mixed (Grossman et al., 1991; Holtgraves, McNamara, 
Cappeart, & Durso, 2010; Levin, Tomer, & Rey, 1992), and it has been suggested (Murray, 2008) 
that basic language abilities (confrontation naming, sentence repetition, comprehension of basic 
commands) may be intact in PD but that more complex aspects of language processing and 
expression may be impaired.  Our findings are consistent with this notion, as PD patients with 
bilateral motor disease displayed intact confrontation naming abilities but were impaired on tasks of 
phonemic and semantic fluency.  The latter language tasks have a strong executive component, and 
thus deficits on these measures may reflect increased executive dysfunction (associated with greater 
disease duration and severity) rather than a true impairment in language abilities.  Within the 
visuospatial domain, the bilateral group demonstrated impairment relative to controls only on a 
measure of spatial judgment and perception (Judgment of Line Orientation).  This also supports 
previous observations that visuospatial impairments are inconsistently observed in PD (Spicer et al. 
1988, Uc et al., 2005), and when observed they seem to be associated with advanced PD rather than 
earlier stages of PD (Huber et al., 1989a).  
 Significant memory retention deficits, for verbal and nonverbal information, were also 
observed in the bilateral group.  The pattern of memory deficits revealed impairment for both 
encoding and retrieval difficulties; therefore, memory difficulties in the bilateral group cannot be 
entirely attributed to encoding difficulties secondary to proposed frontal-striatal involvement in PD, 
as was evident in patients with unilateral disease.  Braak et al. (2004) had asserted that in advanced 
stages of PD, the pathology often reaches the medial temporal lobes as well as other cortical 
structures.  And interestingly, a recent MRI study (Ibarretxe-Bilbao, Tolosa, Junque, & Marti, 2009) 
found significantly reduced hippocampal and amygdala volumes in both demented and nondemented 
PD patients as compared to controls.  Although the study authors did not specify disease 
stage/duration of their PD sample, their finding of medial temporal atrophy in PD is consistent with 
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our results demonstrating significant memory retrieval difficulties in bilateral PD.  Medial temporal 
lobe structures, and particularly the hippocampus, are believed to play an important role in memory 
consolidation and retrieval, and therefore the atrophy of this cortical region may underlie the memory 
dysfunction associated with more advanced PD.  Additionally, the finding of both verbal and non-
verbal memory retrieval deficits in bilateral disease (as well as evidence of language and visuospatial 
difficulties) is suggestive of bilateral cognitive involvement that mirrors the bilateral motor symptom 
progression. 
 In short, present findings suggest that cognitive impairment in PD may be related both to 
laterality of motor symptom at disease onset and current disease stage.  In the early unilateral stages 
within 5 years after onset, cognitive deficits when observed may be restricted mostly to executive 
tasks, and those with right-sided motor symptom onset seem to demonstrate diminished performance 
on executive tasks that are more verbal in nature.  In contrast, PD in the bilateral stage exceeding 5 
years disease duration appears to be associated with more widespread cognitive decline, with those 
with right-sided onset possibly showing more pronounced deficits than those with left-sided onset.         
Motor skills and asymmetry in PD 
 Although motor skills in PD was not a primary focus of this investigation, we also examined 
fine motor performance and motor asymmetry as a function of initial motor symptom laterality in PD 
and current disease progression.  Consistent with group classification, the left-sided onset group 
performed significantly worse than the right-sided onset deficits on both left-handed motor measures.  
However, groups did not differ in their performance on right-handed motor measures.  For the left-
sided onset group, there was a greater discrepancy between left and right hand motor performance 
(with higher scores on the right hand) early in the disease course that seemed to diminish over time, 
presumably as the disease progressed and the dominant right hand became increasingly affected.  In 
contrast, patients with right-sided symptom onset showed an initial smaller asymmetry in motor 
performance, yet with greater disease severity the right-sided group appeared to demonstrate 
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increased motor asymmetry favoring the right hand (although the asymmetry was still less 
pronounced than for the left-sided group).  The increased asymmetry over time in the right-side onset 
group likely parallels increased motor symptoms on the left side as the disease progresses.  These 
results are also consistent with observations that compared to unilateral left hemisphere involvement, 
unilateral right hemisphere pathology tends to be associated with greater intermanual asymmetries 
(Hanna-Pladdy, Mendoza, Apostolos, & Heilman, 2002; Smutok et al., 1989).  Findings in this study 
suggest that intermanual discrepancies in PD patients with initial left-side onset (implying greater 
right hemisphere) become less pronounced over time as the disease course progresses from unilateral 
to bilateral.     
Study limitations and directions for future research  
The current study has several strengths.  First of all, this study uniquely examined the effects 
of both laterality of motor symptoms at disease onset and current disease progression on cognition.  
Secondly, our investigation was restricted to PD groups in the early and middle disease stages, and 
one advantage of studying PD groups earlier in the disease course is the likelihood of studying PD 
without the additional comorbidities that are typical of patients in more advanced disease stages.  
Other strengths of the investigation include use of an extensive battery of tests, inclusion of patient 
groups among three different stages of disease severity, and the utilization of well-matched and 
carefully screened participant groups.     
However, there were some limitations to the current study.  As noted earlier, the relatively 
small sample size may have lowered statistical power, and future similar studies may wish to employ 
larger sample sizes to increase chances of detecting significant differences.  The present study also 
relied on a population of patients from a single Movement Disorders Center in the Midwestern U.S., 
and PD participants in this study were relatively well-educated, with an average of 16 years of formal 
education.  Although PD participants were well-balanced with the controls in education, age, gender, 
and other demographic variables, it is possible that participants in our geographically restricted 
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sample are not representative of the general PD population.  Also, it is important to note that 
significant findings reported in this study refer to statistical significance and are not necessarily 
suggestive of clinical significance.   
In order to examine specific research questions of interest in this study, only select subgroups 
of the PD population were recruited (patients with unilateral disease and less than 5 years disease 
duration and those with bilateral motor disease and having had PD between 5-13 years).  All PD 
participants were in the mild-moderate stage of PD (Hoehn & Yahr score of 1 or 2 only) and we did 
not assess patients at the more severe end of the motor symptom spectrum (e.g., patients with 
prominent balance/gait problems or requiring a wheelchair).  Although there are advantages of such a 
research design as discussed above, study findings may not generalize to PD groups not evaluated in 
this investigation.  Additionally, the current study did not examine differences between motor 
symptomatology subtypes (i.e., patients with tremor only, bradykinesia/rigidity only, or a 
combination of motor symptoms).  Since different motor subtype profiles in PD could possibly 
involve varying pathological processes and foci (Jellinger, 2001), it may be helpful for future studies 
to clarify whether the relationship between laterality of motor symptoms and cognition is affected by 
motor symptom subtype.     
Although this study was not designed to address medication effects, it is unclear to what 
extent PD medications may have affected findings in this investigation.  Nearly all study participants 
were taking a dopamine precursor or a dopamine agonist medication, and the relationship between 
dopamine and cognition is complex and continues to be debated in the literature (Cools, 2008, Pillon 
et al., 2003).  A few participants were also taking anticholingeric medications, which are expected to 
adversely affect cognition.  However, steps were taken in the study to minimize the effects of 
medication differences.  All participants were tested during their “on” state and pharmacological 
interventions employed appeared to be largely similar for the different PD groups of interest.  Yet 
given the high frequency of polytherapy, switching of medications and doses by physicians and 
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patients, it would be helpful for future studies should carefully examine the effects of PD 
medications on cognition.              
In summary, study results suggest the following: a) right-sided motor symptom onset in PD 
appears to be associated with diminished performance on left hemisphere tasks during both unilateral 
and bilateral disease stages, with the lateralizing pattern appearing relatively more pronounced during 
the bilateral stage than the unilateral stage, b) cognitive changes during the unilateral stages of PD 
(irrespective of laterality of motor symptoms) seem restricted to executive dysfunction, and c) 
bilateral motor symptoms in PD (with greater than 5 years disease duration) is associated with more 
widespread cognitive decline believed to reflect greater cortical involvement beyond frontal-striatal 
circuitry dysfunction.  Even though our data was prospectively acquired, this was a cross-sectional 
investigation and more longitudinal studies are needed in order to confirm the nature of cognitive 
changes over the disease course.  Future studies may address the neural basis of cognitive changes 
associated with motor symptomatology in PD.  Neuroimaging data (e.g., functional magnetic 
resonance imaging, positron emission tomography) and post-mortem studies would further help shed 
light on the rate and severity of neurodegeneration in PD.   
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Table 1 
 
Demographic and clinical data for PD and Control Participants 
 
 
    PD participants            Control participants 
                   (n = 60)                       (n = 20) 
 
 
       Mean  SD   Mean   SD 
 
Age    63.9  6.1   65.6  6.8 
Education    16.0  2.3   17.0  1.8 
Gender         71.7% male                65% male  
BDI-II score*   9.1  6.3   3.3  4.0 
MMSE score*   28.6  1.3   29.6  0.7 
AMNART IQ estimate* 117.2  8.6   123.4  3.0 
 
Age at disease onset  59.5  6.1 
Years since PD diagnosis 4.4  3.5 
Years since initial 
symptom onset 6.3  3.9  
UPDRS motor subscore 19.0  5.8 
UPDRS total score  29.9  10.5 
 
   
* p < .01 
 
 55 
Table 2 
 
Demographic and clinical data for right-sided onset and left-sided onset PD groups 
 
  
Right-sided onset      Left-sided onset 
                   (n = 31)                       (n = 29) 
 
 
       Mean  SD   Mean   SD 
 
Age    64.8  6.2   62.9  5.9 
Education    16.0  2.3   16.0  2.4 
Gender          77% male             66% male        
BDI-II score   8.3  5.3   9.9  7.2  
MMSE score   28.5  1.4   28.7  1.1 
AMNART IQ estimate 116.8  8.6   117.7  8.7 
Age at disease onset  60.8  6.4   57.9  7.3  
Years since PD diagnosis 4.0  2.7   5.0  4.2 
Years since initial 
symptom onset 6.0  3.4   6.6  4.5  
Years on PD medications 3.4  2.4   5.0  4.3 
UPDRS motor score  18.5  5.6   19.4  5.6 
UPDRS total score  29.1  10.0   30.6  10.4 
 
   
All above comparisons, including chi square comparisons for gender differences, were n.s. at p > .05   
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Table 3 
 
Demographic and clinical data for PD groups at different disease progression stages  
 
  
        Early unilateral         Middle unilateral  Bilateral 
                  (<1 year post diagnosis)           (2-5 years)        (5 years or greater)    
    (n = 18)     (n = 17)  (n = 25) 
 
 
       Mean (SD)  Mean (SD)  Mean (SD)    
 
Age    62.6 (5.7)  64.4 (7.1)  64.5 (5.8) 
Education    16.1 (2.5)  15.9 (2.7)  16.0 (2.0) 
Gender    61 % males  76% males  75% males         
BDI-II score   7.1 (6.4)  9.1 (6.7)  10.6 (5.8) 
MMSE score   28.7 (1.1)  28.8 (1.3)  28.4 (1.4)   
AMNART IQ estimate 119.2 (7.2)  118.1 (9.4)  115.1 (8.9) 
Age at disease onset  61.7 (5.7)  60.7 (7.1)  56.9 (7.1) 
Years since PD diagnosis** 0.8 (.4)   3.7 (1.1)  7.6 (3.0)  
Years since initial   
symptom onset** 2.7 (2.1)  5.5 (1.8)  9.4 (3.6)  
Years on PD medications** 0.9 (0.2)  3.5 (1.1)  6.8 (3.7) 
UPDRS motor score** 17.7 (4.1)  15.8 (3.9)  22.6 (5.9) 
UPDRS total score**  24.2 (6.5)  25.8 (6.7)  37.5 (10.1) 
 
   
* p < .05 
** p < .01 
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Table 5 
 
Medications prescribed at time of neuropsychological evaluation, for right- and left-sided onset PD 
groups  
 
                Right-sided onset         Left-sided onset 
                                 (n = 31)                           (n = 29) 
 
                      number (%)                       number (%) 
PD medications:  
Synthetic DA and/or DA agonist only 15 (48.4%)    13 (44.8%)  
MAOI only     1 (3.2%)    2 (6.9%) 
COMT-I only     0 (0%)     0 (0%) 
Anticholinergic drug only   0 (0%)     0 (0%) 
Combination of dopaminergic and    
other medication(s)*   15 (48.4%)    12 (41.4%) 
None      0 (0%)                2 (6.9%) 
 
Psychotropic medications: 
Antidepressant only    4 (12.9%)     4 (13.8%) 
Antianxiety only    2 (6.5%)    2 (6.9%) 
Both antidepressant/anxiety   2 (6.5%)    1 (3.4%) 
None      23 (74.1%)    22 (75.9%) 
 
 
* other classes of PD drugs prescribed for the PD sample in conjunction with synthetic dopamine 
(DA) or DA agonists included monoamine oxidase inhibitors (MAOIs), catechol-o-methytransferase 
inhibitors (COMT-Is), anticholinergic drugs, and the experimental drug Creatine.     
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Table 6 
 
Medications prescribed at time of neuropsychological evaluation, for PD groups at different levels of 
disease progression   
 
                   Early unilateral           Middle unilateral    Bilateral 
                            (<1 year post diagnosis)            (2-5 years)           (5 years or greater)    
       (n = 18)     (n = 17)       (n = 25) 
 
               number (%)                   number (%)  number (%) 
PD medications:       
Synthetic DA and/or 
DA agonist only  9 (50.0%)  4 (23.5%)  10 (40.0%) 
MAOI only    3 (16.7%)  0 (0%)   0 (0%) 
COMT-I only    0 (0%)   0 (0%)   0 (0%) 
Anticholinergic drug only  0 (0%)   0 (0%)   0 (0%) 
Combination of dopaminergic   
and other medication(s)* 5 (27.7%)  12 (70.1%)  15 (60.0%) 
None     1 (5.6%)  1 (5.6%)  0 (0%) 
 
Psychotropic medications: 
Antidepressant only   1 (5.6%)  3 (17.6%)  4 (16.0%) 
Antianxiety only   2 (10.2%)  0 (0%)   2 (8.0%) 
Both antidepressant/anxiety  1 (5.6%)  1 (5.9%)  1 (4.0%) 
None     14 (77.7%)  13 (76.5%)  18 (72.0%) 
 
 
* other classes of PD drugs prescribed for the PD sample in conjunction with synthetic dopamine 
(DA) or DA agonists included monoamine oxidase inhibitors (MAOIs), catechol-o-methytransferase 
inhibitors (COMT-Is), anticholinergic drugs, and the experimental drug Creatine. 
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Table 8 
 
Neuropsychological performance of controls and PD groups at different levels of disease 
progression, within each cognitive domain – multivariate and univariate results  
 
    Controls               Early                  Late Bilateral  p value  
                            Unilateral           Unilateral         
    (n=20)        (n = 18)      (n=17)   (n=25) 
 
                                                Mean (SD) Mean (SD) Mean (SD) Mean (SD)  
 
FRONTAL EXECUTIVE – F(4,70) = 1.69            .070 
 
DKEFS verbal switching  14.63 (2.91) 12.89 (3.38) 13.00 (2.55) 12.35 (2.52)      .075 
DKEFS trails switching  75.37 (25.48) 90.61 (44.07) 89.47 (37.84) 125.91 (86.22)      .030 
WCST categories matched 3.68 (1.16) 3.17 (1.58) 3.29 (1.69) 2.39 (1.83)      .070  
Go nogo condition 2   98.47 (1.58) 93.94 (5.86) 95.41 (4.68) 89.13 (17.96)      .041 
             . 
ATTENTION/WORKING MEMORY – F(5,72) = 1.04          .416 
 
Digit span forwards  11.25 (2.31) 10.78 (2.05) 11.00 (2.35) 10.84 (1.91)      .900 
Digit span backwards  8.25 (1.94) 6.61 (1.61) 6.88 (2.40) 6.64 (2.27)           .045 
Spatial span forwards  7.80 (2.07) 7.67 (1.57) 7.41 (1.73) 7.60 (1.71)           .929 
Spatial span backwards8.00 (1.81) 7.44 (1.46) 7.24 (1.35) 6.92 (1.82)           .188 
Letter number sequencing 10.60 (1.85) 9.78 (2.29) 9.59 (1.46) 8.96 (3.27)           .170 
 
LANGUAGE – F(3,74) = 1.22             .285 
 
Boston naming test  14.65 (.93) 14.50 (.71) 14.53 (.72) 14.00 (1.63)         .225 
DKEFS letter fluency  45.60 (9.80) 38.61 (12.83) 38.35 (12.49) 38.04 (12.86)      .148 
DKEFS category fluency 45.20 (7.83) 39.61 (10.25) 41.00 (11.52) 37.42 (9.51)         .063 
 
VISUOSPATIAL – F(3,74) = 1.22             .269 
 
Judgment of line orientation 13.45 (1.32) 11.89 (3.74) 12.47 (1.23) 11.72 (2.11)      .074 
Visual form discrimination  30.90 (1.74) 30.22 (2.21) 29.71 (2.69) 29.60 (2.45)         .253 
DKEFS visual scanning 23.35 (6.60) 25.06 (4.34) 25.59 (6.72) 27.04 (10.11)      .444 
 
MEMORY ENCODING  – F(2,75) = 3.90            .001 
 
CVLT-II learning trials28.95 (3.00) 26.33 (4.47) 25.65 (2.98) 23.52 (4.34)      .000 
Visual reproduction I  82.90 (10.30) 80.50 (12.16) 81.88 (13.15) 74.12 (12.65)      .072 
 
MEMORY RETENTION  – F(2,75) = 3.73           .002 
 
CVLT-II delayed free recall  7.45 (1.36) 6.44 (1.38) 6.65 (1.46) 5.40 (1.78)      .000 
Visual reproduction II  70.35 (15.29) 64.94 (20.53) 60.94 (17.69) 55.92 (16.77)      .053 
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Table 10   
 
Results of planned comparisons between controls and PD groups, by disease stage 
 
         Controls      Controls         EU and       EU and          Controls            
          and EU            and LU            LU           bilateral    and bilateral       
      
 
FRONTAL EXECUTIVE            
DKEFS verbal switching             n.s.         n.s.       n.s.             n.s.  .006  
DKEFS trails switching             n.s.         n.s.                 n.s.  .025  <.003 
WCST categories matched            n.s.               n.s.                 n.s.  n.s.  .005 
Go nogo condition 2              n.s.         n.s.       n.s.  n.s.  <.003 
       
ATTENTION/WORKING MEMORY  
Digit span forwards             n.s.               n.s.        n.s  n.s.  n.s. 
Digit span backwards            .009        .003                 n.s. n.s.  .006 
Spatial span forwards             n.s.               n.s.                  n.s. n.s.  n.s. 
Spatial span backwards           n.s.               n.s.                  n.s. n.s.  n.s. 
Letter number sequencing            n.s.               n.s.                  n.s. n.s.  n.s. 
 
LANGUAGE  
Boston naming test             --        --                    --  n.s.  n.s. 
DKEFS letter fluency             --        --                     --  n.s.  <.005 
DKEFS category fluency            --        --                     --  n.s.  .02 
 
VISUOSPATIAL  
Judgment of line orientation            --                 --                     --  n.s.  .007 
Visual form discrimination             --        --                     --  n.s.  n.s. 
DKEFS visual scanning                     --        --                     --  n.s.  n.s. 
 
MEMORY ENCODING           
CVLT-II learning trials          .019              .005                 n.s. <.001  * 
Visual reproduction I            n.s.        n.s.                   n.s. n.s.  .009 
 
MEMORY RETENTION   
CVLT-II delayed free recall             --                  --                      --  .015  * 
Visual reproduction II            --        --                      --  .05  .004 
 
 
* Contrast not examined because Bonferroni post-hoc comparison had already revealed significant 
pairwise difference.  
 
Note.  EU = early unilateral group , LU = late unilateral group.  All p values reported above were 
significant at the one-tailed level after Bonferroni-Holm adjustments to correct for Type I error. 
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Table 12 
 
Classification matrix for discriminant function analysis of select neuropsychological measures, for 
control vs. patient group membership   
 
 
 
       Predicted group membership  
 
Group         Control       PD patient    Total 
 
 
Control   14  6   20   
 
PD patient     13  47   60 
 
 
Note.  76.3% of the cases were correctly classified. 
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Figure 1 
 
PD group interactions on motor asymmetry scores 
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